NT5E and head and neck squamous cell carcinoma: Collectively, our results highlight the potential for predictive pretreatment immune biomarkers in HNSCC and provide a warrant for further evaluation of CD39 and CD73 as biomarkers or as part of immune signatures in HNSCC.